Engineering Antibody Fragments for Enhanced Drug Load & Functionality: The Story of ANT-045, A cMET Targeting FDC
Time: 11:00 am
day: Conference Day 2
Details:
- Explore the unique design features of Antikor’s Fragment-Drug Conjugates (FDCs) and learn about our FDC discovery platform, navigating the complexities of conjugating multiple payloads onto smaller antibody fragments, highlighting the importance of an optimised payload-linker
- Delve into the discovery of Antikor’s lead FDC program (ANT-045) and how we have mitigated aggregation and optimised key properties like affinity, drug-loading, and pharmacokinetics to produce a novel, potent and well-tolerated drug for difficult solid tumours
- Review the development of ANT-045 in advanced cMET models for tumour cure efficacy, safety and tolerability against Abbv-399, highlighting the benefits of increased tumour penetration that smaller-formats bring
